Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01452854
Other study ID # UCSF 10-03288
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date October 2011
Est. completion date November 2013

Study information

Verified date July 2022
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to look at how a chemotherapy treatment (Temozolomide, also called Temodar) affects the process of ovarian aging which is measured by a decline in ovarian follicle count, in patients with Low Grade Glioma (LGG). It is important to know if different patient factors and Temozolomide influence the rate of ovarian aging in women with LGG who have good long-term survival rates. This will allow better counseling about the effects of this particular chemotherapy agent on fertility in women.


Description:

Understanding how Temozolomide influences ovarian aging would be important information for physicians to predict the possibility of infertility (the inability to become pregnant) following recovery from Temozolomide treatment. Physicians would like to provide better individualized recommendations for cancer patients regarding timing of planned treatment and future pregnancy. We will do this by comparing data from the women being treated for Low Grade Glioma with Temozolomide to a similar group of women who have been unaffected by cancer or cancer treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date November 2013
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 44 Years
Eligibility Inclusion Criteria: - Premenopausal women ages 18-44 newly diagnosed with LGG - Patients fulfill the inclusion criteria for UCSF Protocol Number: CC #99102 " A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients with Supratentorial Low Grade Glioma" - Patients with histologically proven supratentorial low grade glioma. - Patients may or may not have had a surgical resection. - Patients must be expected to live the length of study - Patients must be able to provide informed consent according to institutional guidelines. Exclusion Criteria: - Prior ovarian resection, unilateral or bilateral oophorectomy, hysterectomy or radiation to pelvic region. - Pregnancy or breast feeding. - Diagnosis of another malignancy, unless the patient was diagnosed at least 2 years earlier and has been disease-free for at least 6 months following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed. - Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results. - Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). - Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse - Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or is not in the best interest of the patient.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States UCSF Center for Reproductive Health San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Francisco Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ovarian Aging (AFC and Hormones) Transvaginal Ultrasound will be use to measure Antral Follicle Counts (AFC) and blood will be drawn to measure hormones (FSH, LH, estradiol, estrone, AMH, SHBG, testosterone, and inhibin B). Every 3 months for 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT04044937 - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms Phase 2
Recruiting NCT03952598 - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy N/A
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT05964569 - Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma Phase 2
Completed NCT02607397 - ROCOCO - Low Grade Glioma - Planning Study N/A
Active, not recruiting NCT01358058 - Proton Radiation Therapy for Gliomas N/A
Recruiting NCT03718767 - Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype Phase 2
Recruiting NCT02455245 - A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Phase 3
Completed NCT02186262 - Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas
Terminated NCT02023905 - Everolimus With and Without Temozolomide in Adult Low Grade Glioma Phase 2
Recruiting NCT01386450 - AZD6244 in Children With Low-Grade Gliomas Phase 1/Phase 2
Completed NCT02286531 - Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma N/A
Active, not recruiting NCT04553757 - Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
Not yet recruiting NCT06132685 - Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial Phase 2
Recruiting NCT04166409 - A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma Phase 3
Recruiting NCT02358187 - A Vaccine Trial for Low Grade Gliomas Phase 2
Recruiting NCT03871257 - A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma Phase 3
Terminated NCT01281982 - (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
Active, not recruiting NCT01288235 - Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation Phase 2